Study details
Enrolling now
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
Zenas BioPharma (USA), LLC
NCT IDNCT06559163ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
190
Study length
about 2 years
Ages
18–70
Locations
16 sites in CA, FL, GA +6
What this study is about
Researchers are testing obexelimab, a treatment, in people with systemic lupus erythematosus (SLE). The trial will last about 743 days and involve taking obexelimab or a placebo once per week for 24 weeks. It also includes follow-up visits to monitor safety and effectiveness.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Obexelimab
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
monoclonal antibody
Body systems
Immune